NeurologyLive

07/02/2025

At 2025, researchers reported that the pivotal TRANQUIL study met its primary end point, with the Fasikl's investigational wearable Felix NeuroAI wristband demonstrating superiority over a sham device in reducing and improving users' ability to perform daily activities. American Academy of Neurology (AAN)

Read More:

In late-breaking findings from the TRANQUIL study presented at AAN 2025, the wearable demonstrated significant improvements in tremor reduction and daily functioning over a sham device.

07/02/2025

At 2025, researchers presented the design of a phase 3 study that will test the efficacy and safety of EPX-100, a 1st generation antihistamine agent, as a potential treatment for patients with Lennox-Gastaut syndrome, a rare epileptic disorder. American Academy of Neurology (AAN)

Read More:

Harmony Biosciences’ phase 3 study will assess EPX-100, a repurposed antihistamine, as a potential treatment for Lennox-Gastaut syndrome, targeting seizure reduction and improved outcomes.

07/02/2025

Recently at the 2025 , Lauren B. Krupp, MD, of NYU Langone Health, had a conversation with NeurologyLive® on why early, high-efficacy treatment may be important for pediatric patients with . American Academy of Neurology (AAN)

Watch Now: https://hubs.li/Q03vjxpr0

07/01/2025

Marcia Pasqualini, PhD, of Avila University, discussed at how cognitive behavioral therapy and social support can help to improve quality of life for individuals with 🧠

Watch interview: https://hubs.li/Q03vkjQq0
[📽️: 4 minutes]

The professor of psychology at Avila University discussed how cognitive behavioral therapy and social support can help to improve quality of life for individuals with Parkinson disease. [WATCH TIME: 4 minutes]

07/01/2025

After positive phase 3 results, Apnimed plans to submit AD109 to the FDA in early 2026 for . If approved, it would be the first drug to tackle both airway obstruction and oxygen loss, marking a major milestone in sleep apnea treatment 👏

Discover more about the trial: https://hubs.li/Q03vkbk20

07/01/2025

A new 5-pillar care model presented at is reshaping how are managed. Developed by Jennifer Corcoran, MD at University of Rochester Medical Center, the approach emphasizes holistic care, proactive support, and communication that puts patients at the center🏩

Watch the interview: https://hubs.li/Q03vksnd0
[📽️: 5 minutes]

The movement disorder neurologist at University of Rochester Medical Center outlined a 5-pillar model that emphasized holistic care, patient-centered communication, and proactive support in movement disorders. [WATCH TIME: 5 minutes]

07/01/2025

2025 has already brought pivotal phase 3 results in AD, migraine, neuromuscular disease & more 📈🧬

We’ve compiled the most impactful trial data so far—insights that are actively shaping neuro care & drug development:
🔗https://hubs.li/Q03vqjvB0

07/01/2025

🚨 Positive MESA trial update: Sevasemten showed 18-month NSAA improvements in patients with Becker MD 🧬💪

Edgewise also reported encouraging DMD data (LYNX/FOX) & a completed FDA Type C meeting—advancing the path toward the first BMD therapy.
🔗

Edgewise Therapeutics reveals promising results for sevasemten, potentially the first approved treatment for Becker muscular dystrophy, enhancing patient outcomes.

07/01/2025

Check out our handpicked, potentially groundbreaking trial readouts from the first half of 2025: Spanning sleep apnea, , , , and rare neurodegenerative disorders, these data offer critical insights into therapeutic efficacy, safety, and trial design innovation! 💡

📲Read now: https://hubs.li/Q03vkqg20

07/01/2025

🧬 Stay current on genetic testing guidelines for Alzheimer disease. Learn through interactive cases in this free CME/CE. Start now to help guide your patients with confidence.
👉 https://hubs.li/Q03rSJLl0

This continuing education is brought to you by our accredited partner, PER.

06/30/2025

Learn strategies for enhancing early diagnosis of . Watch our
On-Demand presentation, ALS Frontiers: Accelerating Diagnosis
and Access in Rare Disease to hear from our experts. Watch now. bit.ly/4hYGlMI

06/30/2025

Newly presented findings from the RESOLUTION trial (NCT05452239) showed that treatment with 100 mg doses of eptinezumab (Vyepti; Lundbeck) led to statistically significant reductions in frequency of migraine days and monthly acute medication use in patients with chronic migraine (CM) with medication-overuse headache.

Our coverage:

New findings reveal eptinezumab significantly reduces migraine days and medication use in chronic migraine patients, offering hope for effective treatment.